Some chemicals in our environment act like fake hormones, tricking the body into storing fat or blocking insulin. This work identifies specific biological 'red flags' in the liver and pancreas to spot this damage early. It's like finding a specific fingerprint that proves a chemical caused a health problem rather than just guessing.
Companies struggle to predict how new chemicals affect human metabolism, often relying on outdated animal tests that don't accurately reflect human liver or pancreas reactions.
The project is building 3D human liver microtissues and predictive in silico models to identify biomarkers for metabolic disruption.
If you are a diagnostic kit manufacturer dealing with a lack of specific tests for chemical-induced diabetes — this project developed effect biomarkers that allow for precise detection of metabolic disruption.
If you are a specialty chemical producer dealing with strict EU safety regulations — this project developed alternative testing models using 3D liver microtissues that reduce the need for animal testing.
If you are a drug development firm dealing with unpredictable metabolic side effects in clinical trials — this project developed predictive models for adverse metabolic outcomes that improve risk assessment.
Based on available project data, specific pricing or implementation costs are not provided as this is a research project.
The project focuses on developing 3D liver microtissues and in silico models; however, industrial scale-up data is not explicitly detailed in the current report.
Based on available project data, the licensing terms are not specified, though the project aims to improve testing guidelines and risk assessment models.
The project aims to provide mechanistic data and predictive models to answer unmet regulatory needs regarding endocrine-disrupting chemicals.
The project period runs from 2024-01-01 to 2028-12-31, suggesting that final validated models will be available toward the end of 2028.
The consortium is heavily academic, with 10 universities and 3 research institutes, indicating a strong focus on fundamental discovery. However, the inclusion of 2 industry partners (13% ratio) and 1 SME suggests a pathway for translating these biological findings into commercial diagnostic or testing tools.
Contact University of Helsinki (ITA-SUOMEN YLIOPISTO) in Finland
Contact SciTransfer to explore licensing opportunities for 3D liver microtissue models.
